New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCartalax vs Exenatide

Cartalax vs Exenatide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Cartalax
GLP-1 / Weight Loss AgonistsCognitive Enhancement
Exenatide
Summary
Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
Half-Life
Short (minutes); gene-regulatory effects are sustained
~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
5 mcg, titrate to 10 mcg
Frequency
Daily for 10–30 days
Twice daily
Key Benefits
  • Supports cartilage matrix synthesis and maintenance
  • May slow progression of osteoarthritic cartilage degradation
  • Reduces chondrocyte apoptosis
  • Promotes joint longevity in aging and high-impact sports
  • Anti-aging effects on connective tissue
  • Complementary to BPC-157 and TB-500 in joint recovery protocols
  • Well tolerated in available human and animal research
  • Blood glucose control in type 2 diabetes
  • Weight loss (average 2–3 kg in clinical trials)
  • Once-weekly extended-release formulation available
  • Reduces appetite and food intake
  • Possible neuroprotective in Parkinson's disease (Phase II trials)
  • Reduces systemic inflammation
  • May protect pancreatic beta cells
  • Cardiovascular neutral or potentially protective
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant adverse events reported at standard doses
  • Nausea (most common, especially initially)
  • Vomiting
  • Diarrhea
  • Headache
  • +4 more
Stacks With